Literature DB >> 7796128

Involvement of nitric oxide in intracerebroventricular beta-endorphin-induced neuronal release of methionine-enkephalin.

S Hara1, E R Kuhns, E A Ellenberger, J L Mueller, T Shibuya, T Endo, R M Quock.   

Abstract

Previous work has suggested that the antinociceptive effect of nitrous oxide (N2O) in rats is mediated, at least in part, by beta-endorphin (beta-EP) and that centrally administered beta-EP stimulates release of methionine-enkephalin (ME) in the rat spinal cord. Since inhibition of central nitric oxide (NO) production has been found to suppress N2O antinociception, we examined the possible involvement of NO in the release of spinal cord ME by i.c.v. beta-EP. Urethane-anesthetized, male Sprague-Dawley rats were intrathecally (i.t.) perfused with artificial cerebrospinal fluid (aCSF) and fractions of perfusate were assayed for immunoreactive (i.r.) ME. The beta-EP-induced increase in ME concentration in the i.t. perfusate was significantly suppressed by perfusing the animal with aCSF containing 100 microM L-NG-nitro arginine (L-NOARG), an inhibitor of NO synthase (NOS). The further addition of 50 microM L-arginine (L-ARG), but not D-arginine (D-ARG), to the aCSF reversed the suppression of the ME change by L-NOARG. However, the potency of L-ARG decreased with increasing concentrations of L-ARG. On the other hand, increasing the concentration of L-NOARG in the aCSF to 250 microM failed to produce a greater suppression of the beta-EP-induced increase in ME. These findings suggest that NO may mediate the beta-EP-induced release of ME in the spinal cord and that interference with this mechanism might be an explanation for the antagonism of N2O antinociception in rats by NOS inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796128     DOI: 10.1016/0006-8993(95)00065-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice.

Authors:  Yao Zhang; Lindsay P Quock; Eunhee Chung; Yusuke Ohgami; Raymond M Quock
Journal:  Eur J Pharmacol       Date:  2011-01-14       Impact factor: 4.432

2.  Nitrous oxide-induced NO-dependent neuronal release of β-endorphin from the rat arcuate nucleus and periaqueductal gray.

Authors:  Yusuke Ohgami; Eunhee Chung; Raymond M Quock
Journal:  Brain Res       Date:  2010-11-06       Impact factor: 3.252

Review 3.  Advances in understanding the actions of nitrous oxide.

Authors:  Dimitris E Emmanouil; Raymond M Quock
Journal:  Anesth Prog       Date:  2007

Review 4.  Neurobiology of nitrous oxide-induced antinociceptive effects.

Authors:  Masahiko Fujinaga; Mervyn Maze
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

5.  NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models.

Authors:  Daniela Ronchetti; Valentina Borghi; Gema Gaitan; Juan F Herrero; Francesco Impagnatiello
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

6.  Antagonism of the antinociceptive effect of nitrous oxide by inhibition of enzyme activity or expression of neuronal nitric oxide synthase in the mouse brain and spinal cord.

Authors:  Jessica Lack Cope; Eunhee Chung; Yusuke Ohgami; Raymond M Quock
Journal:  Eur J Pharmacol       Date:  2009-10-08       Impact factor: 4.432

7.  Nitrous oxide-antinociception is mediated by opioid receptors and nitric oxide in the periaqueductal gray region of the midbrain.

Authors:  Dimitris E Emmanouil; Andrea S Dickens; Rick W Heckert; Yusuke Ohgami; Eunhee Chung; Shujie Han; Raymond M Quock
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-01       Impact factor: 4.600

8.  Exposure to nitrous oxide stimulates a nitric oxide-dependent neuronal release of beta-endorphin in ventricular-cisternally-perfused rats.

Authors:  Lisa M Zelinski; Yusuke Ohgami; Raymond M Quock
Journal:  Brain Res       Date:  2009-09-09       Impact factor: 3.252

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.